- Journal List
- Int J Cardiol Heart Vasc
- v.53; 2024 Aug
- PMC11327605
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Int J Cardiol Heart Vasc. 2024 Aug; 53: 101456.
Published online 2024 Jul 25. doi:10.1016/j.ijcha.2024.101456
PMCID: PMC11327605
PMID: 39156916
Aman Goyal,a Hritvik Jain,b Surabhi Maheshwari,c Jyoti Jain,b Ramez M. Odat,d Humza Saeed,e Mohamed Daoud,f,⁎ Gauranga Mahalwar,g and Kamna Bansalh
Author information Article notes Copyright and License information PMC Disclaimer
Associated Data
- Supplementary Materials
Graphical abstract
Open in a separate window
Keywords: Atrial fibrillation, Inflammatory bowel disease, Risk, Meta-analysis
Abstract
Background
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a prevalent condition associated with chronic noninfectious inflammation of the gastrointestinal tract. It has been hypothesized that chronic inflammation can predispose patients to atrial fibrillation (AF), however, no clear evidence exists to support this.
Methods
A systematic literature search was conducted using major databases aimed at studies focusing on AF development in patients with IBD. Further subgroup analyses were performed for ulcerative colitis (UC) and crohn’s disease (CD). Risk ratios (RR) with their corresponding 95% confidence intervals (CI) were pooled using a random-effects model in the Review Manager Software. Statistical significance was set at p<0.05.
Results
Seven studies with 88,893,407 patients were included (1,002,719 and 87, 890, 688 patients in the IBD and non-IBD groups, respectively). IBD patients were at an increased risk of developing AF [RR: 1.52; 95% CI: 1.19–1.95; p=0.0009] compared to the non-IBD group. In subgroup analyses, patients with UC were at an increased risk of developing AF [RR: 1.29; 95% CI: 1.08–1.53; p=0.004], as were CD patients [RR: 1.30; 95% CI: 1.07–1.58; p=0.008] compared to the non-UC and non-CD groups, respectively.
Conclusion
Patients with IBD are at nearly 1.5 times the risk of developing AF compared to the non-IBD population. Our meta-analysis was limited by heterogeneity among the studies, highlighting the importance of further large-scale prospective studies to establish more robust evidence.
1. Introduction
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is a prevalent clinical condition, with over 240 cases per 100,000 people in 2019 in the United States [1]. IBD is a waxing and waning condition characterized by episodes of inflammation in the gastrointestinal tract, caused by an abnormal response to the gut microflora [2]. Recent investigations have demonstrated an increased risk of cardiovascular diseases in patients with IBD due to the common interplay of risk factors such as obesity, diabetes mellitus, smoking, and diet [3]. IBD has been linked to an increased risk of coronary artery disease, peripheral arterial disease, stroke, deep vein thrombosis, and pulmonary embolism [4].
Interestingly, IBD has also been hypothesized to increase the risk of atrial fibrillation (AF), the most commonly encountered cardiac arrhythmia in clinical practice. The potential mechanistic link may involve systemic inflammation, autonomic dysfunction, and oxidative stress associated with IBD, as well as shared risk factors such as age, obesity and hypertension between the two conditions. Medications used to treat IBD may also play a role in the development of AF in these patients [5]. This hypothesis also stems from the fact that inflammation can act as a trigger for AF [6], [7].
The relationship between IBD and AF is not well-established, with inconsistent data on the association between the two conditions. This highlights the need for a comprehensive meta-analysis to systematically evaluate the risk of AF in patients with IBD compared to the general population. Hence, we conducted a meta-analysis to provide the most comprehensive pooled analysis of existing data on the risk of AF in patients with IBD.
2. Materials and Methods
This systematic review and meta-analysis were reported in line with the guidelines laid by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [8]. We registered the pre-specified study protocol in the International PROSPERO registry under CRD42024534122.
2.1. Search strategy and eligibility criteria
A comprehensive literature searches of major electronic databases, such as Medline (via PubMed), Embase, Cochrane Library, Scopus, and the International Registry of Clinical Trials (https://www.clinicaltrials.gov), was performed from inception to March 2024. The search strategy for this meta-analysis was a combination of keywords and predefined Medical Subject Headings (MeSH) such as “inflammatory bowel disease”, “ulcerative colitis”, “Crohn’s disease”, “atrial fibrillation”, “auricular fibrillation”, “persistent atrial fibrillation”, and “paroxysmal atrial fibrillation”. We used the Boolean operators “AND” and “OR” to create the search strategy. The search strategy was modified according to the requirements of each database, as shown in Supplementary Table S1. The search was aimed at retrieving records that adhered to the following criteria: (i) Randomized controlled trials (RCTs) or observational studies, (ii) IBD patients in one group, (iii) non-IBD patients as controls, and (iv) assessment of the development of AF. Abstracts without published full texts, review articles, case reports, case series, editorials, correspondences, and viewpoint publications were excluded. Subsequently, duplicates were removed from all records using the EndNote Reference Library X7 software (Clarivate Analytics, Philadelphia, USA).
2.2. Data extraction and quality assessment
The following data were extracted from each study: author name, publication year, study design, country, number of participants, inclusion criteria, age group, male sex, diabetes mellitus, hypertension, dyslipidemia, and follow-up duration. Two investigators (H.J. and L.F.) extracted the data in an Excel spreadsheet, and a third investigator (A.G.) was consulted to resolve any discrepancies. Quality assessment of all observational studies was conducted using the Newcastle-Ottawa Scale (NOS) [9].
2.3. Data synthesis
All statistical analyses pertaining to this review were performed using Review Manager Software (version 5.4). We pooled dichotomous outcomes using risk ratios (RR) and their corresponding 95% confidence intervals using the Mantel-Haenszel random-effects model. Statistical heterogeneity was evaluated using the Higgins I2 metric, with<25% as low, 25–75% as moderate, and any value greater than 75% as severe heterogeneity. We conducted a subgroup analysis by dividing patients into IBD subtypes: ulcerative colitis (UC) and Crohn’s disease (CD). To explore heterogeneity, we used the leave-one-out method by consecutively omitting one study at a time to identify the study contributing the most to heterogeneity. Publication bias was assessed by using funnel plots. Statistical significance for pooled effect estimate was considered if the 95% CI did not cross the numeric value “1″ and the two-tailed p-value was less than 0.05.
3. Results
3.1. Study selection
A preliminary search using a predefined strategy yielded 529 records. After removing duplicates (n=184), 345 records were subjected to preliminary screening by title and abstract assessment. We excluded 312 studies during the screening and subjected the remaining 33 studies to assessment of their respective full-texts. Subsequently, 26 articles were excluded during the full-text assessment for various reasons: ineligible outcomes (n=15), no control group (n=4), or different study design (case reports/series, letters, reviews) (n=7). Finally, seven studies were included in the meta-analysis [18], [19], [20], [10], [11], [12], [13]. The study selection process is depicted in the PRISMA flowchart in Supplementary Figure S1.
3.2. Study and patient characteristics
A total of 88,893,407 patients were included, with 1,002,719 and 87, 890, 688 patients in the IBD and non-IBD groups, respectively. All seven included studies were observational in design. The publication years of the included studies ranged from 2014 to 2023.Mean ages ranged from 36.5 to 64.4years and male to female ratio was comparable across the studies. Five of the included studies report about the presence of diabetes (2–16%), hypertension (3–43%), and dyslipidemia (4–20%) in the IBD groups. The baseline and demographic characteristics of the studies are shown in Table 1.
Table 1
Baseline characteristics of included studies.
| Author Name (Year) | Study Design | Country | Number of patients; n | Inclusion Criteria | Age; “mean±SD” OR “median (IQR)’ | Males (%) | Diabetes Mellitus (%) | Hypertension (%) | Dyslipidemia (%) | Follow-up Duration (years); “mean±SD” OR “median (IQR)” | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IBD | C | IBD | C | IBD | C | IBD | C | IBD | C | IBD | C | IBD | C | ||||
| Baek 2016 | Retrospective cohort | South Korea | 3143 | NA | Patients diagnosed with ARD and AF who were admitted to Severance Hospital between 2005–2015. | 36.5±17.1 | NR | 59.1 | NR | 4.7 | NR | 8.3 | NR | 4.8 | NR | 6.7±4.4 | |
| Choi 2019 | Retrospective cohort | South Korea | 37,696 | 113,088 | Patients diagnosed with IBD between January 1, 2010 and December 31, 2014 from NHIS database. | 39.4±16.4 | 39.42±16.4 | 61 | 61 | 3.9 | 4.7 | 10.9 | 12.1 | 6.7 | 7.0 | 4.9±1.3 | |
| Kristensen 2014 | Retrospective cohort | Denmark | 24,499 | 236,275 | All Danish citizens aged 15years or more at the time of initial diagnosis of CD or UC between 1 January 1996 and 31 December 2011 were included, if they within 1year before or after diagnosis claimed a prescription for pharmacological IBD treatment. | 43.9±19.1 | 43.2±18.7 | 46.1 | 45.9 | 2 | 0.8 | 3.3 | 1.3 | NR | NR | 6.8 | 6.9 |
| Mubasher 2020 | Retrospective cohort | United States of America | 84 7,235 | 84,757, 349 | Patients (≥18years) diagnosed with IBD and cardiac arrhythmias (AF, atrial flutter, SVT, VT, VF) admitted between 2012 and 2014 from the AHRQ's NIS database. | 52.45 | 57.41 | 43.09 | 40.9 | 16.23 | 25.29 | 31.40 | 39.10 | 20.22 | 29.53 | NR | NR |
| Pattanshetty 2015 | Retrospective cohort | United States of America | 16 | 125 | A diagnosis of UC or CD using EMR review between January 2001 and December 2010 | 64.4±10.7 | 51.6±15.7 | NR | NR | 12.5 | 8.1 | 43.8 | 24.6 | NR | NR | 7.9±3.8 | 7.3±3.5 |
| Sun 2023 | Retrospective cohort | Sweden | 83,877 | 22,248 | A diagnosis of IBD using ESPRESSO, a nationwide histopathology cohort, between 1969 and 2017 (using the SNOMED system) | NR | |||||||||||
| Tilly 2023 | Prospective cohort | United Kingdom | 6128 | 494,072 | Participants from the UK Biobank database were screened for rheumatic fever, gastrointestinal autoimmune diseases, musculoskeletal and connective tissue autoimmune diseases, and neurological autoimmune diseases, between 2006 and 2022. | NR | 12.8 (1.6) | ||||||||||
Open in a separate window
Abbreviations: IBD: Inflammatory bowel disease; C: Control; ARD: Autoimmune rheumatic diseases; AF: atrial fibrillation; NHIS: National Health Insurance Service; UC: Ulcerative colitis; CD: Crohn’s disease; AHRQ: Agency for Healthcare Research and Quality; NIS: National Inpatient Sample; SVT: supraventricular tachycardia; VT: ventricular tachycardia; VF: ventricular fibrillation; EMR: Electronic medical records; ESPRESSO: Epidemiology Strengthened by histopathology Reports in Sweden; SNOMED: Systematized Nomenclature of Medicine; UK: United Kingdom and NR: Not reported.
3.3. Outcomes
Data comparing IBD and non-IBD groups were reported in six studies [18], [19], [10], [11], [12], [13]. IBD patients were at an increased risk of developing AF [RR: 1.52; 95% CI: 1.19–1.95; p<0.0009; I2:99%] compared to the non-IBD group. No reduction in heterogeneity was observed in the sensitivity analysis.
In subgroup analyses, UC patients were at an increased risk of developing AF [RR: 1.29; 95% CI: 1.08–1.53; p=0.004; I2=94%] compared to the non-UC group. The removal of Kristensen et al. [11] reduced heterogeneity to zero. Similarly, CD patients also demonstrated an increased risk of AF development [RR: 1.30; 95% CI: 1.07–1.58; p=0.008; I2=86%] compared to the non-CD group, and the removal of Choi et al. [10] reduced heterogeneity to 49% (Fig. 1).
Fig. 1
Individual and pooled analyses comparing atrial fibrillation (AF) risk in patients with inflammatory bowel disease (IBD). A: Inflammatory bowel disease; B: Ulcerative colitis subgroup; C: Crohn’s disease subgroup. Risk ratios (RR) with 95% confidence intervals (CI) are depicted on a logarithmic scale. The diamond symbolizes the combined or overall effect.
3.4. Quality assessment and publication bias
For quality appraisal of the included studies, we utilized NOS for observational studies. All studies were deemed “high quality” as depicted in Supplementary Table S3. Visual inspection of funnel plots was performed to assess possible publication bias, which demonstrated a low risk of bias (Supplementary Figure S2).
4. Discussion
Emerging research suggests a link between IBD and an increased likelihood of developing atherosclerotic cardiovascular diseases, heart failure, and AF [3]. This comprehensive meta-analysis delves into the intricate relationship between IBD and the development of AF.
Our findings indicate that individuals with IBD are at significantly increased risk of AF compared to those without the condition [RR: 1.52; 95% CI: 1.19–1.95]. Among patients with IBD, those diagnosed with UC show a slightly higher risk of AF compared to those with CD. These results align with a previous meta-analysis by Zuin et al., which included three studies. Their analysis revealed an elevated risk of AF in IBD patients [OR: 2.26; 95% CI: 2.11–2.41] [21]. A key strength of our study is the inclusion of larger number of studies compared to prior analyses. This expanded data set strengthens the generalizability and robustness of our conclusions.
Furthermore, our findings are supported by a prospective population-based UK Biobank (UKB) study, which demonstrated significant links between autoimmune diseases and the risk of developing new-onset AF. This study, encompassing around half a million participants, revealed substantial associations between new-onset AF and various autoimmune diseases, including rheumatic fever without heart involvement, gastrointestinal diseases (such as CD and UC), and musculoskeletal diseases (such as rheumatoid arthritis, psoriatic and enteropathic arthropathies, polyarteritis nodosa, systemic lupus erythematosus, and systemic sclerosis) [20]. Another longitudinal study by Kristensen et al. using Danish national healthcare records observed a similar increase in AF incidence specifically during periods of active IBD [11]. Interestingly, a study utilizing the U.S. National Inpatient Sample Database presented a contrasting perspective. This analysis found that IBD patients, typically younger, more often female, and with a higher smoking prevalence, exhibited lower rates of most arrhythmias compared to the general population. Notably, the exception was supraventricular tachycardia, which was more prevalent in the IBD group [19].
Chronic inflammation emerges as a pivotal factor linking IBD to AF [14]. Numerous studies have elucidated the intricate interplay between inflammation and cardiac electrophysiology, proposing mechanisms such as structural remodelling of atrial tissue, autonomic dysfunction, and oxidative stress. The chronic inflammatory state associated with IBD can lead to fibrosis and hypertrophy in the atrial tissue, creating a substrate conducive to the development and maintenance of AF. IBD has also been linked to autonomic nervous system imbalance, characterized by increased sympathetic activity and decreased parasympathetic tone, which can predispose individuals to AF by altering the electrical properties of the atria. Furthermore, elevated oxidative stress in IBD can cause direct damage to the atrial myocardium and promote AF by inducing inflammation and fibrosis [5], [15], [16].
Further research corroborates our findings, further substantiating the heightened risk of AF in IBD patients. Notably, investigations into the molecular pathways underlying inflammation-induced arrhythmogenesis have underscored the role of pro-inflammatory cytokines, immune cell infiltration, and fibrosis in promoting atrial substrate remodelling conducive to AF development [5], [17]. Inflammatory molecules such as tumor necrosis factor, interleukin-1, and interleukin-6 which are characteristically elevated in IBD, have been shown to impact both the electrical and structural aspects of the heart, thereby increasing the risk of AF Moreover, elevated levels of the inflammatory marker C-reactive protein have been associated with a higher likelihood of developing or exacerbating AF. Some evidence also links the involvement of soluble CD40 and CD40L pathways, which are activated in patients with IBD, with the duration of non-valvular AF. These potential mechanisms underscore the complex interplay between inflammation, autonomic dysfunction, oxidative stress, and structural remodelling in the development of AF in IBD patients (Fig. 2). Further research is needed to elucidate the precise pathways and identify potential therapeutic targets to mitigate the increased risk of AF in this patient population.
Fig. 2
Schematic summarizing the cascade of events associating Inflammatory Bowel Disease (IBD) and Atrial Fibrillation (AF). *IBD: Inflammatory Bowel Disease; AF: Atrial fibrillation; TNF: Tumour Necrosis factor; IL: Interleukin; CRP: C-reactive protein; CD: Cluster of differentiation.
This current meta-analysis underscores the clinical imperative of integrating AF screening into the holistic management of IBD patients. Recognizing AF as a potentially debilitating complication of IBD necessitates proactive surveillance strategies aimed at early detection and intervention. Leveraging insights from previous studies, clinicians can adopt tailored screening protocols, incorporating electrocardiographic monitoring and risk assessment tools to identify high-risk individuals promptly. By doing so, clinicians can mitigate the substantial burden of AF-related complications, including stroke, heart failure, and thromboembolic events, thereby optimizing patient outcomes.
4.1. Limitations
The results of this study must be interpreted with caution for several reasons. Firstly, the small number of total studies may be underpowered to detect statistical significance. Secondly, all of the included studies were observational. Observational studies are at an inherently higher risk of bias and they establish correlation but no causality. It is also crucial to note the lack of mechanistic insights in the included studies. Third, we observed high heterogeneity in all outcomes, which we attempted to address via sensitivity analyses. However, this could introduce variability and affect the reliability of the effect estimate. Lastly, this meta-analysis did not account for asymptomatic AF, thus underestimating the actual AF risk. Nonetheless, this current study highlights the clinical importance of integrating AF screening in IBD patients to mitigate poor outcomes.
4.2. Future directions
Future research should explore the impact of confounding variables such as disease severity, medication usage, and lifestyle factors on the observed association between IBD and AF. Using Mendelian randomization studies to analyse available genetic data (possibly from UKB) could help identify shared genetic loci associated with these conditions. It is also essential to investigate the age and gender distribution of AF cases and controls. Furthermore, it is important to determine if patients with IBD, who likely develop AF earlier than those without IBD, also have an earlier onset of AF compared to non-IBD controls. Longitudinal studies, augmented by advanced imaging modalities and biomarker assessments, offer promise in elucidating the temporal dynamics of inflammation-driven arrhythmogenesis and refining risk stratification strategies. Moreover, investigations into the therapeutic potential of anti-inflammatory agents, immunomodulatory therapies, and lifestyle interventions hold promise in attenuating the heightened risk of AF in IBD patients.
5. Conclusions
Patients with IBD are at higher risk of developing AF as compared to non-IBD individuals. Routine AF screening in IBD management is crucial to reduce the burden of AF-related complications in these patients. Multicenter, large-scale randomized trials are warranted to corroborate the results of this study.
CRediT authorship contribution statement
Aman Goyal: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Software, Supervision, Writing – original draft, Writing – review & editing. Hritvik Jain: Conceptualization, Data curation, Investigation, Methodology, Resources, Supervision, Writing – original draft. Surabhi Maheshwari: Conceptualization, Data curation, Writing – original draft, Writing – review & editing. Jyoti Jain: Investigation, Methodology, Writing – original draft, Writing – review & editing. Ramez M. Odat: Supervision, Validation, Writing – original draft. Humza Saeed: Writing – original draft, Writing – review & editing. Mohamed Daoud: Conceptualization, Supervision, Validation, Visualization, Writing – review & editing. Gauranga Mahalwar: Validation, Writing – review & editing. Kamna Bansal: Conceptualization, Supervision, Validation, Visualization, Writing – review & editing.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Footnotes
Appendix ASupplementary data to this article can be found online at https://doi.org/10.1016/j.ijcha.2024.101456.
Appendix A. Supplementary data
The following are the Supplementary data to this article:
Supplementary Data 1:
Click here to view.(215K, docx)
References
1. Wang R., Li Z., Liu S., Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. 2023;13(3):e065186. [PMC free article] [PubMed] [Google Scholar]
2. McDowell C., Farooq U., Haseeb M. StatPearls [internet]. Treasure Island (FL) StatPearls Publishing; 2024. Inflammatory bowel disease. [cited 2024 Apr 24]. Available from. [PubMed] [Google Scholar]
3. Chen B., Collen L.V., Mowat C., Isaacs K.L., Singh S., Kane S.V., et al. Inflammatory Bowel Disease and Cardiovascular Diseases. Am J Med. 2022;135(12):1453–1460. [PubMed] [Google Scholar]
4. Wu H., Hu T., Hao H., Hill M.A., Xu C., Liu Z. Inflammatory bowel disease and cardiovascular diseases: a concise review. European Heart Journal Open. 2022;2(1) [PMC free article] [PubMed] [Google Scholar]
5. Konstantinou C.S., Korantzopoulos P., Fousekis F.S., Katsanos K.H. Inflammatory bowel disease and atrial fibrillation: a contemporary overview. Eur. J. Gastroenterol. Hepatol. 2023;35(7):695. [PubMed] [Google Scholar]
6. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., et al. Worldwide epidemiology of atrial fibrillation. Circulation. 2014;129(8):837–847. [PMC free article] [PubMed] [Google Scholar]
7. Jain H., Odat R.M., Goyal A., Jain J., Dey D., Ahmed M., et al. Association between psoriasis and atrial fibrillation: A Systematic review and meta-analysis. Curr Probl Cardiol. 2024;49(6) [PubMed] [Google Scholar]
8. M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International Journal of Surgery (2021):88;105906. Ann Intern Med. 2015 Jun 2;162(11):777-84. 10.7326/M14-2385. PMID: 26030634.
9. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. [PubMed] [Google Scholar]
10. Choi Y.J., Choi E.K., Han K.D., Park J., Moon I., Lee E., et al. Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study. World J Gastroenterol. 2019;25(22):2788–2798. [PMC free article] [PubMed] [Google Scholar]
11. Kristensen S.L., Lindhardsen J., Ahlehoff O., Erichsen R., Lamberts M., Khalid U., et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. EP Europace. 2014;16(4):477–484. [PubMed] [Google Scholar]
12. Pattanshetty D.J., Anna K., Gajulapalli R.D., Sappati-Biyyani R.R. Inflammatory bowel “cardiac” disease: Point prevalence of atrial fibrillation in inflammatory bowel disease population. Saudi J Gastroenterol. 2015;21(5):325–329. [PMC free article] [PubMed] [Google Scholar]
13. Sun J., Roelstraete B., Svennberg E., Halfvarson J., Sundström J., Forss A., et al. Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study. PLoS Med. 2023;20(10):e1004305. [PMC free article] [PubMed] [Google Scholar]
14. Patel P., Dokainish H., Tsai P., Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21(9):1064–1070. [PubMed] [Google Scholar]
15. Guo Y., Lip G.Y.H., Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–2270. [PubMed] [Google Scholar]
16. Harada M., Van Wagoner D.R., Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79(3):495–502. [PMC free article] [PubMed] [Google Scholar]
17. Rungoe C., Nyboe Andersen N., Jess T. Inflammatory bowel disease and risk of coronary heart disease. Trends Cardiovasc Med. 2015;25(8):699–704. [PubMed] [Google Scholar]
18. Baek Y.S., Kim T.H., Uhm J.S., et al. Prevalence and the clinical outcome of atrial fibrillation in patients with Autoimmune Rheumatic Disease. Int J Cardiol. 2016;214:4–9. [PubMed] [Google Scholar]
19. Mubasher M., Syed T., Hanafi A., Yu Z., Yusuf I., Abdullah A.S., Mohamed M.F., Alweis R., Rao M., Hoefen R., Danjuma M.I. An investigation into the association between inflammatory bowel disease and cardiac arrhythmias: An examination of the united states national inpatient sample database. Clin Med Insights Cardiol. 2020;28(14) [PMC free article] [PubMed] [Google Scholar]
20. Tilly M.J., Geurts S., Zhu F., Bos M.M., Ikram M.A., de Maat M.P.M., de Groot N.M.S., Kavousi M. Autoimmune diseases and new-onset atrial fibrillation: a UK Biobank study. Europace. 2023;25(3):804–811. [PMC free article] [PubMed] [Google Scholar]
21. Zuin M., Zuliani G., Rigatelli G., Favero G.D., Roncon L. Atrial fibrillation in patients with inflammatory bowel disease: A systematic review and meta-analysis. Eur J Intern Med. 2020;76:120–122. doi:10.1016/j.ejim.2020.02.029. [PubMed] [CrossRef] [Google Scholar]
Articles from International Journal of Cardiology. Heart & Vasculature are provided here courtesy of Elsevier
